EP3607056A1 - Mikrokompartment maligner hämatopoietischer zellen und verfahren zur herstellung solch eines mikrokompartments - Google Patents
Mikrokompartment maligner hämatopoietischer zellen und verfahren zur herstellung solch eines mikrokompartmentsInfo
- Publication number
- EP3607056A1 EP3607056A1 EP18718897.4A EP18718897A EP3607056A1 EP 3607056 A1 EP3607056 A1 EP 3607056A1 EP 18718897 A EP18718897 A EP 18718897A EP 3607056 A1 EP3607056 A1 EP 3607056A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- microcompartment
- lymphoma
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000003211 malignant effect Effects 0.000 title claims description 32
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims description 22
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 93
- 239000000017 hydrogel Substances 0.000 claims abstract description 93
- 230000001413 cellular effect Effects 0.000 claims abstract description 54
- 239000002775 capsule Substances 0.000 claims abstract description 48
- 238000012216 screening Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 366
- 210000002536 stromal cell Anatomy 0.000 claims description 54
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 42
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 42
- 210000002744 extracellular matrix Anatomy 0.000 claims description 42
- 238000004132 cross linking Methods 0.000 claims description 34
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 30
- 229940072056 alginate Drugs 0.000 claims description 30
- 235000010443 alginic acid Nutrition 0.000 claims description 30
- 229920000615 alginic acid Polymers 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 230000003394 haemopoietic effect Effects 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 230000005684 electric field Effects 0.000 claims description 3
- 210000004524 haematopoietic cell Anatomy 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 93
- 239000010410 layer Substances 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 38
- 238000005538 encapsulation Methods 0.000 description 22
- 239000000725 suspension Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000001125 extrusion Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 150000001768 cations Chemical class 0.000 description 9
- 201000003444 follicular lymphoma Diseases 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 5
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000011254 conventional chemotherapy Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012604 3D cell culture Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000722 protumoral effect Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- 239000000182 glucono-delta-lactone Substances 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000007261 regionalization Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000032765 Device extrusion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- -1 methacrylate compound Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the invention relates to a method for preparing microcompartmental cells comprising malignant haematopoietic cells.
- the invention also relates to such cellular micro-compartments and to their use, in particular in the pharmaceutical field, for the screening and identification of molecules of interest likely to treat a hematological malignancy.
- Cancers of hematopoietic tissues, or hematological malignancies, are characterized by a disorder of the multiplication and differentiation of cells of a blood line.
- the most common malignant hemopathies include leukemias and lymphomas.
- Leukemia is a cancer of bone marrow cells, which is characterized by abnormal and massive proliferation of precursors of incompletely differentiated white blood cells, to the detriment of red blood cells, normal white blood cells and platelets.
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- AML acute myeloblastic leukemia
- CML chronic myeloid leukemia
- Lymphoma is a group of cancers of the lymphatic system that originates in a secondary lymphoid organ and can spread to all parts of the lymphatic system.
- lymphoma There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).
- NHLs are cancers whose incidence has been increasing for 40 years in developed countries and which ranks as the 10th most cancers in terms of frequency.
- lymphomas are formed and evolve within the secondary lymphoid organs comprising several types of cells (microenvironmental cells and lymphoma cells), which interact with each other within an extracellular matrix via soluble and membrane molecules, and are subjected to bio-mechanical forces. All of these factors affect the development of lymphoma, but also the response to treatment. However, 2D models do not reproduce these phenomena and are therefore only weakly representative of the pathophysiological processes of lymphomas.
- animal models have been developed in which human cancer cells are grafted or injected. Such animal models are however expensive, difficult to reproduce, and generally not representative of the physiological phenomena of human hematological malignancies.
- 3D cancer cell cultures have been developed. These 3D cultures are particularly interesting for studying the mechanisms of progression of cancers and better testing anti-cancer treatments. Indeed, cells cultured in 3D within a matrix or in aggregates, have an architecture closer to the tissue and the tumor and show an expression of their genes similar to that of the tumor in vivo (Gravelle et al, 2014 Am. J. Pathol 184: 2082-295, Weiswald et al., 2009, Br. J. Cancer 101: 473-482). In addition, models of 3D co-cultures mimicking cancer cell / stromal cell interactions can at least partially reproduce the tumor niche and study the consequences on tumor progression or drug resistance.
- 3D models of lymphomas are generally obtained using collagen sponges (Kobayashi et al., Trends Immunol 31: 422-428), the so-called “hanging drop” technique (Gravelle et al., 2014. Am., J. Pathol. : 282-295) or a polystyrene architecture (Caicedo-Carvajal et al. J. Tissue Eng 2011: 362326).
- these techniques have many disadvantages, both in terms of costs and reproducibility, making them irrelevant for the industrial scale study of new drugs.
- the developed 3D cultures do not include any element of the tumor microenvironment, thus limiting their relevance.
- the inventors have found that by coextruding a hydrogel solution with a solution of cells comprising lymphoma cells, and optionally lymphoid-type stromal cells, i.e., close to stromal cells that infiltrate lymphomas, and extracellular matrix, said cells aggregated within the hydrogel capsule to organize themselves into a cell mass approximating the cellular organization within a lymphoma. Furthermore, depending on the type of cells coextruded with the hematopoietic malignant cells, the inventors have discovered that it is possible to recreate a tumor niche mimicking a tumor niche in vivo.
- microcompartments in which the nature of the cells and the intercellular interactions are substantially similar to those observed within a lymphomatous tumor niche, or leukemia.
- the cellular microcompartments developed according to the invention are particularly relevant as 3D models of hematological malignancies, in particular for the screening and the identification of new candidate molecules for the treatment of lymphomas and / or leukemias.
- the process according to the invention makes it possible to obtain very large quantities of microcompartment of perfectly controlled dimensions.
- the microcompartments obtained are easy to manipulate, making them particularly suitable for use on a large scale, particularly in the pharmaceutical field.
- the subject of the invention is therefore a method for preparing a cellular microcompartment comprising an aggregate of cells containing malignant hematopoietic cells encapsulated in a hydrogel layer, according to which a hydrogel solution and a solution of cells comprising hematopoietic cells. malignancies are co-extruded concentrically and then crosslinked.
- the cell solution comprises lymphoma cells or leukemic cells.
- the invention also relates to a microcompartment cell capable of being obtained by the method according to the invention, wherein said microcompartment comprises an aggregate of cells comprising at least malignant haematopoietic cells, encapsulated in a hydrogel layer.
- a cellular microcompartment consists of a single cell aggregate encapsulated in a hydrogel layer.
- said microcompartment comprises an aggregate of cells, consisting solely of lymphoma cells, encapsulated in a hydrogel layer. In another embodiment, the microcompartment comprises an aggregate of cells, consisting solely of leukemic cells, encapsulated in a hydrogel layer.
- said microcompartment comprises an aggregate of cells composed in particular of lymphoma cells and lymphoid-type stromal cells, as well as an extracellular matrix layer between the cell aggregate and the hydrogel layer.
- said microcompartment comprises an aggregate of cells composed in particular of leukemic cells and medullary-type stromal cells, as well as an extracellular matrix layer between the cell aggregate and the hydrogel layer.
- the invention also relates to a cellular microcompartment comprising a cell aggregate encapsulated in a hydrogel layer, wherein the cell aggregate comprises malignant hematopoietic cells, such as lymphoma cells or leukemic cells, and stromal cells, said microcompartment further comprising an extracellular matrix layer between the cell aggregate and the hydrogel layer.
- a cellular microcompartment comprising a cell aggregate encapsulated in a hydrogel layer, wherein the cell aggregate comprises malignant hematopoietic cells, such as lymphoma cells or leukemic cells, and stromal cells, said microcompartment further comprising an extracellular matrix layer between the cell aggregate and the hydrogel layer.
- the invention also relates to a method for screening or identifying a compound for the treatment and / or prevention of a lymphoma comprising the steps of: (a) contacting a cellular microcompartment according to the invention, optionally free of a hydrogel layer, with a test compound;
- the invention also relates to a use of a cellular microcompartment according to the invention for the screening or identification of a compound for the treatment of a hematological malignancy, such as lymphoma or leukemia.
- Figure 1 Encapsulation of SUDHL4 and HLY1 lymphoma cells in an alginate capsule.
- SUDHL4 and HLY1 cells express GFP.
- Figure 1A shows images of the phase contrast and fluorescence capsules at different times (J1-J11) after encapsulation, the images being acquired with an Olympus CKX41 microscope (x10 objective).
- Figure 1B shows the growth curves measured for the cell clusters inside the alginate capsules from the photos, using the ImageJ® software.
- FIG. 2 Cell microcompartment formation according to the invention comprising only lymphomatous or leukemic cells (A) or lymphomatous or leukemic cells, and stromal cells (B).
- A lymphomatous or leukemic cells
- B stromal cells
- 1 hydrogel capsule
- 2 capsule light
- 3 lymphoma cells
- 4 growth phase
- S hydrogel capsule containing a cluster of lymphoma cells
- 6 dissolution step of the hydrogel capsule
- 7 cluster of lymphoma cells
- 8 extracellular matrix layer
- 9 stromal cells
- 10 growth phase
- 11 hydrogel capsule containing a cluster of lymphoma and stromal cells
- 12 cluster of lymphoma and stromal cells.
- FIG 3 Microcompartmental cells comprising a cluster of follicular lymphoma cells of the DOHH2 line and of lymphoid-type stromal cells (RESTO, Ame-Thomas Blood 2007; 109: 693) in an alginate capsule covered with an internal layer of Matrigel ® to J9 after encapsulation. The images were obtained in phase contrast using a Leica DMI8 microscope (x10 objective).
- Figure 4 Dissolution of the cell microcellular alginate capsule comprising a cluster of follicular lymphoma cells of line DOHH2 (A) and a cluster of follicular lymphoma cells of line DOHH2 and RESTO cells (B) on day 9 after encapsulation.
- Figure S Flow cytometric analysis of dead cells in clusters of cells comprising SUDHL4 (SA) lymphoma cells or HLY1 (B) lymphoma cells after different encapsulation times.
- Figure 6 Analysis of the residual effect of the stromal tumor niche on the growth of lymphoma cells. Images of cellular micro-compartments in an alginate capsule coated with an internal Matrigel® layer comprising only RESTO (A) cells, only DOHH2 (B) lymphoma cells, RESTO cells and DOHH2 (C) lymphoma cells. The images were obtained in phase contrast using a Leica DMI8 microscope (x10 objective). The scale bar is the same for all three images.
- FIG. 7 Comparative effects of Etoposide (A) and Cisplatin (B) on cell death after contacting, for 48 hours, a suspension of HLY1 cells (suspension) or a HLY1 cell cluster derived from a cellular microcompartment according to the invention, comprising only lymphomatous cells, with increasing doses of etoposide ( ⁇ g / ml) or cisplatin ( ⁇ M).
- FIG. 8 Microcompartment cell showing differentiation of stromal cells into pro-tumoral lymphoid stroma.
- Cellular microcomponents comprising a cluster of follicular lymphoma cells of the DOHH2 line and lymphoid-type stromal cells RESTO in an alginate capsule coated with an internal layer of Matrigel® at D8 after encapsulation.
- CD20 (revealing B-cell), GFP (revealing RESTO cells) and TG2 markings were made on a fixed spheroid and embedded in paraffin.
- the image was taken under a confocal microscope LSM510 objective x20.
- the image on the right is the superposition of the first three images.
- Arrows indicate RESTO cells (GFP +) expressing TG2.
- Figure 9 Study of the diffusion of doxorubicin in SUDHL4 cells cultured in suspension or in spheroids.
- SUDHL4 cells cultured in suspension or after 7 days in 3D in the presence or absence of extracellular matrix (ECM) (Mg: matrigel) and RESTO cells are treated for 24 hours with doxorubicin ( ⁇ ). After dissociation of the cells cultured in 3D, the fluorescence intensity of the cells was analyzed by flow cytometry.
- ECM extracellular matrix
- Figure 10 Representative images showing the penetration of antibodies in the cellular microcompartment.
- SC-GFP + Microcompartment containing DLBCL SUDHL4 cells cultured in 3D in the presence of ECM.
- B Labeling with Rituximab (RTX) - 633.
- the capsules are incubated for 12h with AC, then they are imaged with a microscope confocal Zeiss LSMS10 to the x25 lens.
- the nuclei are marked with DAPI in blue.
- the outline of the capsules is visible (marked at the periphery on the images).
- Figure 11 Comparison of the cytotoxic effects of doxorubicin and etoposide on cells of DLBCL SUDHL4 grown in 2D (suspension) or in 3D ⁇ ECM ⁇ Resto. Cells or spheroids at J7 post-encapsulation are treated for 48 hours with drugs. At the end of the treatment, the cell viability is measured using the CellTiter-Glo® 3D Cell Viability Assay® kit (Promega).
- FIG. 12 Cellular Cell Micromembrane Formation According to the Invention as a Function of Time from T Cells in Primary Culture from a Patient With Sezary Lymphoma
- the cells are labeled with calcein-AM to visualize live cells and with propidium iodide (PI) to visualize dead cells.
- PI propidium iodide
- the nuclei are stained with DAPI.
- D10 days after encapsulation
- the invention relates to a cellular microcompartment, in 3D, comprising an aggregate, or cluster, of malignant hematopoietic cells encapsulated in a hydrogel envelope.
- the terms “hydrogel layer”, “hydrogel capsule” or “hydrogel envelope” denote a three-dimensional structure formed from a matrix of polymer chains swollen with a liquid, and preferentially some water.
- the polymer or polymers of the hydrogel layer are crosslinkable polymers when subjected to a stimulus, such as a temperature, a pH, ions, etc.
- the hydrogel used is biocompatible, in that it is not toxic to the cells.
- the hydrogel layer must allow the diffusion of oxygen and nutrients to feed cells in the cell microcompartment and allow their survival.
- the hydrogel layer also passes test molecules, such as pharmaceutical molecules.
- the polymers of the hydrogel layer may be of natural or synthetic origin.
- the outer layer of hydrogel contains one or more polymers among sulfonate-based polymers, such as sodium polystyrene sulfonate, acrylate-based polymers, such as sodium polyacrylate, polyethylene glycol diacrylate, the gelatin methacrylate compound, polysaccharides, and especially polysaccharides of bacterial origin, such as gellan gum, or of plant origin, such as as pectin or alginate.
- the outer hydrogel layer comprises at least one of alginate.
- the outer layer of hydrogel comprises only alginate.
- alginate is understood to mean linear polysaccharides formed from ⁇ -D-mannuronate (M) and ⁇ -L-guluronate (G), salts and derivatives thereof.
- the alginate is a sodium alginate, composed of more than 80% of G and less than 20% of M, with an average molecular mass of 100 to 400 kDa (for example: PRONOVA® SLG100) and at a total concentration of between 0.5% and 5% by weight (weight / volume).
- the hydrogel layer comprises polymers capable of limiting cell adhesion ("cell-repellent"), such as natural polysaccharides (for example sodium alginate), or polymers comprising polyethylene glycol units, so that to facilitate, where appropriate, the separation of said hydrogel layer from the cluster of cells that it covers or its degradation without affecting the structure of the cell aggregate.
- cell-repellent such as natural polysaccharides (for example sodium alginate), or polymers comprising polyethylene glycol units
- the cell compartment according to the invention is characterized by the presence, in the internal volume of the hydrogel envelope, of an aggregate of cells organized in a cohesive cluster in which the cells interact.
- the cell aggregate comprises malignant hematopoietic cells.
- malignant hematopoietic cells is meant cancer cells derived from the differentiation of lymphoid (i.e., lymphocytes) or myeloid (i.e., erythrocyte, leukocyte, platelet) progenitors.
- lymphoid i.e., lymphocytes
- myeloid i.e., erythrocyte, leukocyte, platelet
- the hematopoietic malignant cells are chosen from lymphomatous cells and leukemic cells.
- the cell aggregate contained in the hydrogel outer envelope comprises lymphoma cells.
- lymphoma cells refer to lymphoid malignant cells.
- the lymphoma cells are chosen from follicular lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, mantle cell lymphoma, peripheral T lymphoma, lymphoblastic lymphoma, anaplastic lymphoma, lymphoma of the zone marginal, lymphoma of MALT ("Mucosa- associated lymphoid tissue"), lymphoma of the lymphoplasmocyte, and / or lymphoma of the spleen, cutaneous T-cell lymphoma, cutaneous B-cell lymphoma.
- the cell aggregate contained in the hydrogel outer envelope comprises leukemic cells.
- leukemic cells denote malignant blood cells.
- the leukemic cells may be selected from acute myeloblastic leukemia cells, chronic myeloid leukemias, chronic lymphoid leukemias, acute leukemias.
- malignant hematopoietic cells can come from cellular models, but also be obtained from patients.
- the use of lymphoma or leukemia cells from a particular patient may be particularly interesting in the context of personalized medicine, for the identification of molecule (s) particularly adapted (s) to the treatment of lymphoma or leukemia of said patient .
- the tumor cells of the patient are advantageously purified before use.
- the purification is done by negative selection, in order to avoid the introduction of antibodies into the cell culture.
- the cell aggregate of the cellular microcompartment comprises only lymphoma cells.
- the organization of lymphoma cells into a cohesive cell cluster within the hydrogel capsule makes it possible to confer on these cells resistance to the penetration of external molecules that is close to the resistance observed in the cells of a lymphoma.
- the cell aggregate of the cellular microcompartment comprises only leukemic cells.
- the cell aggregate comprises, in addition to malignant hematopoietic cells, stromal cells.
- the nature of the stromal cells chosen depends advantageously on the nature of the associated hematopoietic malignant cells.
- the microcompartment further comprises an extracellular matrix layer. Indeed, the inventors have shown that the presence of an extracellular matrix is necessary for the adhesion and survival of stromal cells and for the formation of the aggregate of mixed cells within the hydrogel capsule.
- the extracellular matrix layer advantageously tapes the inner face of the hydrogel envelope.
- the extracellular matrix layer comprises a mixture of proteins and extracellular compounds promoting cell culture, and more particularly that of stromal cells.
- the extracellular matrix comprises structural proteins, such as laminins containing the ⁇ 1, ⁇ 4 or ⁇ 5 subunits, the ⁇ or ⁇ 2 subunits, and the ⁇ or ⁇ 3 subunits of entactin and vitronectin. , fibronectin, laminin, collagen, as well as growth factors, such as TGF-beta and / or EGF.
- the extracellular matrix layer consists of, or contains Matrigel® and / or Geltrex®.
- the malignant hematopoietic cells are lymphoma cells and the stromal cells are lymphoid stromal cells, such as adipose tissue stem cells (ADSCs), or more particularly, cells of the type RESTO.
- Stromal cells of the RESTO type are lymphoid stromal cells derived from tonsils ("tonsil-derived stromal cells"). Isolation and characterization of RESTO cells can be done according to the protocol described in the publication Amé-Thomas et al. Blood 2007. The tonsils are cut into pieces and then incubated in a solution containing DNAse I and collagenase IV. The cell suspension is then deposited on a Percoll® gradient.
- RESTO stomal cells
- CD4S hematopoietic cell markers
- CD10S mesenchymal cell markers
- RESTO cells are known to have characteristics close to those of fibroblastic reticular cells of secondary lymphoid organs: secretion of chemokines, fibronectin and a transglutaminase network in response to TNF ⁇ (Tumor Necrosis Factor) and LTaip2 (LymphoToxin) .
- TNF ⁇ Tumor Necrosis Factor
- LTaip2 LTaip2
- the cell aggregate may comprise, in addition to lymphoma cells, cells normally present in the microenvironment of a lymphoma.
- the term "cells of the microenvironment" refers to the cells present in the aggregate of cells that are not lymphomatous cells.
- the cell aggregate can also comprise, in addition to stromal cells, cells of the immune system, such as macrophages.
- malignant hematopoietic cells are leukemic cells and stromal cells are medullary stromal cells, such as HS-S line cells, or bone marrow Mesenchymal Stromal Cells (MSCs).
- stromal cells are medullary stromal cells, such as HS-S line cells, or bone marrow Mesenchymal Stromal Cells (MSCs).
- the ratio of lymphoma cells / stromal cells in the cell aggregate is between 1/1 and 1000/1.
- the ratio may vary over time, the amount of lymphoma cells tending to increase exponentially compared to stromal cells.
- the ratio of lymphoma cells / stromal cells is between 1/1 and 10000/1.
- the cell density in the cellular microcompartment at D8 is between one hundred and several thousand cells.
- a microcompartment with a diameter of 200 ⁇ preferably comprises 100 to 10,000 cells.
- the microcompartment cell is closed. It is the outer layer of hydrogel that gives its size and shape to the cellular microcompartment.
- the microcompartment can have any shape compatible with encapsulation of cells, including a spheroidal, ovoid or tabular shape.
- the cell aggregate is constrained in the internal volume of said hydrogel layer, and once the cells are confluent, the aggregate can no longer increase in volume.
- the microcompartment cell has a diameter or a smaller dimension between 50 ⁇ and 600 ⁇ . "Smallest dimension" means twice the minimum distance between a point on the outer surface of the hydrogel layer and the center of the microcompartment.
- the thickness of the hydrogel outer layer represents 5% to 30% of the radius of the microcompartment.
- the "thickness" of a layer is the dimension of said layer extending radially with respect to the center of the microcompartment.
- the cellular microcompartment has a diameter or a smaller dimension of between 50 ⁇ and 300 ⁇ . Such dimensions ensure that all of the cells in the cell aggregate, including those in the center of said cell aggregate, have sufficient access to oxygen and nutrients that diffuse through the hydrogel layer. Thus, no phenomenon of hypoxia and / or necrosis is observed within such a microcompartment, all cells having sufficient access to small molecules that diffuse through the hydrogel envelope.
- the cellular microcompartment has a diameter or a smaller dimension between 500 ⁇ and 600 ⁇ .
- cells in the center of the cell aggregate have little or no access to oxygen and nutrients that diffuse through the hydrogel wrap.
- Such microcompartments are particularly interesting for the study of the phenomena of hypoxia and / or necrosis which can sometimes occur in a lymphoma.
- the invention also relates to methods of preparing microcompartmental cells for obtaining cell microcompartments comprising an aggregate of cells containing malignant hematopoietic cells encapsulated in an outer hydrogel envelope. After encapsulation of the cells, they will reorganize within the hydrogel envelope, so as to form a cohesive cluster.
- the encapsulation is done by means of a concentric coextrusion process, in which the hydrogel solution is coextruded with the cell solution, before being crosslinked by means of a crosslinking solution capable of crosslinking the hydrogel.
- Concentric coextrusion it is meant that the solutions are coextruded so that one solution surrounds the other solution.
- the concentric coextrusion is such that the hydrogel solution surrounds the cell solution.
- drops of coextruded solutions then fall into the crosslinking solution, comprising a crosslinking agent capable of crosslinking the hydrogel and thus forming a hydrogel capsule around the cells.
- the solutions are coextruded directly in the crosslinking solution, so as to form an outer hydrogel tube in which the cells will be organized.
- drops of coextruded solutions pass through a crosslinking aerosol (made from a crosslinking solution) so as to allow at least partial crosslinking of the hydrogel layer around the drop of solution of cells.
- the partially crosslinked microcompartments then fall into a crosslinking solution where the crosslinking is terminated.
- any extrusion process for concentrically coextruding hydrogel and cells can be used.
- the process according to the invention is implemented by means of a concentric double-wall extrusion device as described in patent FR2986165.
- crosslinking solution means a solution comprising at least one crosslinking agent adapted to crosslink a hydrogel comprising at least one hydrophilic polymer, such as alginate, when it is applied. contact with it.
- the crosslinking solution may be, for example, a solution comprising at least one cation divalent.
- the crosslinking solution may also be a solution comprising another known crosslinking agent of the alginate or of the hydrophilic polymer to be crosslinked, or a solvent, for example water or an alcohol, adapted to allow crosslinking by irradiation or by any other means. other technique known in the art.
- the crosslinking solution is a solution comprising at least one divalent cation.
- the divalent cation is a cation that makes it possible to crosslink alginate in solution.
- H may be for example a divalent cation selected from the group consisting of Ca 2+ , Mg 2+ , Ba 2+ and Sr 2 "1" , or a mixture of at least two of these divalent cations.
- the divalent cation, such as Ca 24 ⁇ may be associated with a counterion to form, for example, CaCl or CaCCh type solutions, well known to those skilled in the art.
- the crosslinking solution may also be a solution comprising CaC0 3 coupled to Glucono delta-lactone (GDL) forming a solution of CaCOs-GDL.
- the crosslinking solution may also be a mixture of CaCO 3 -CaSO 4 -GDL.
- the crosslinking solution is a solution comprising calcium, in particular in the Ca 2+ form.
- the crosslinking solution may also be a solution comprising polylysine.
- the divalent cation concentration in the crosslinking solution is between 10 and 1000 mM.
- the crosslinking solution may comprise other constituents, which are well known to those skilled in the art, than those described above, in order to improve the crosslinking of the hydrogel sheath under the conditions, in particular time and / or temperature, special.
- the hydrogel solution is coextruded with a solution of cells.
- the cell density in the cell solution is between 1 ⁇ 10 6 and 100 ⁇ l cells / ml.
- the cell solution used for coextrusion contains only lymphomatous cells suspended in culture medium.
- the cell solution used for coextrusion contains only leukemic cells suspended in culture medium.
- the cell solution used for coextrusion comprises lymphoma cells and lymphoid stromal cells, suspended in an extracellular matrix.
- the number ratio of lymphoma cells / stromal cells in the cell solution is between 1/1 and 1/2.
- such a solution may also comprise immune cells, preferentially chosen from macrophages.
- the number ratio of lymphoma cells / microenvironment cells in the cell solution is advantageously between 1/1 and 1/2.
- the cell solution used for coextrusion comprises leukemic cells and medullary stromal cells, suspended in an extracellular matrix.
- the ratio in number of leukemic cells / stromal cells in the cell solution is between 1/1 and 1/2.
- the cell suspension advantageously represents between 50 and 95% of the volume of the solution, while the extracellular matrix represents between 5 and 50% of said volume.
- coextrusion also involves an intermediate solution, including sorbitol.
- the coextrusion is carried out so that the intermediate solution is extruded between the hydrogel solution and the cell solution.
- the extrusion rate of the hydrogel solution is between 5 and 100 mlVh, preferably between 15 and 60 mIJh.
- the extrusion rate of the cell solution is between 5 and 100 mJh, preferably between 10 and 50mIVh.
- the extrusion rate of the intermediate solution is between 5 and 100 mJh, preferably between 10 and 50 mlVh.
- the coextrusion rate of the different solutions can be easily modulated by those skilled in the art, so as to adapt the diameter or the smallest dimension of the cellular microcompartment and / or the thickness of the hydrogel layer.
- the extrusion rates of the cell solution and the intermediate solution are identical.
- the extrusion rate of the hydrogel solution is substantially equal to the extrusion rate of the cell solution and optionally of the intermediate solution.
- the hydrogel solution, the intermediate solution and the cell solution are loaded into three concentric compartments of a coextrusion device, so that the solution of Hydrogel, forming the first stream, surrounds the intermediate solution that forms the second stream, which itself surrounds the cell solution that forms the third stream.
- the tip of the device extrusion, through which the three flows out, opens above the crosslinking solution.
- the tip of the extrusion device is located about 50 cm, +/- 10 cm, of the crosslinking solution.
- An electric field is generated at the output of the coextrusion device, to allow the formation of microdroplets.
- a copper ring is disposed about 1 cm at the exit of the coextrusion device.
- Microdroplets thus fall sequentially into the crosslinking bath where the hydrogel layer is crosslinked, forming an outer shell around the cells.
- the tip of the extrusion device opens into a crosslinking aerosol, formed by microdroplets of crosslinking solution, so that the hydrogel layer of the microdroplets begins to crosslink in contact with the microdroplets of the aerosol .
- the crosslinking may, if appropriate, continue in a crosslinking solution in which the microdroplets are received.
- the method according to the invention makes it possible very rapidly to obtain several thousand microcompartments that are substantially identical in terms of size and composition.
- the method according to the invention makes it possible to encapsulate malignant hematopoietic cells, such as lymphomatous cells, in an external hydrogel envelope. After only a few hours, the cells contained in the hydrogel envelope reorganize, so as to aggregate and form a cluster of cells that becomes cohesive after a few days.
- the microcompartment cell obtained by coextrusion is maintained in a suitable culture medium for two to twelve days before being used, preferably between four and ten days. This latency advantageously allows the cells to aggregate and form a cell cluster mimicking the cluster of cells in a lymphoma.
- the cell microcompartment obtained by coextrusion as such, that is to say with the external hydrogel shell. It is otherwise possible to proceed before any use to hydrolysis of the hydrogel shell, in order to recover the aggregate of cells. It is also possible to freeze the cell microcompartment obtained by coextrusion (with the hydrogel casing) for later use.
- microcompartment cell according to the invention can be used for many applications, particularly for pharmacological purposes.
- microcompartmental cells according to the invention can in particular be used for identification and / or validation tests of candidate molecules having an action on hematological malignancies.
- candidate molecules having an action on hematological malignancies.
- the permeability of certain hydrogels is sufficient to pass molecules having a molecular weight less than or equal to 200 kDa. It is therefore possible to study these molecules directly on the microcompartment cell. In the case of molecules of higher molecular weight, it is possible to hydrolyze the outer hydrogel shell before performing the tests. Thus, ⁇ study is done directly on ⁇ clusters of cells.
- the hydrolysis of the hydrogel casing is performed 6 or 10 days after the coextrusion, so as to ensure that the cluster of cells is well formed and that the cells are cohesive.
- the cellular microcompartments according to the invention can also be used in personalized medicine, using cells of a subject presenting a lymphoma or leukemia, in order to specifically test the reaction of said subject to different treatments, before selecting the most appropriate treatment for said subject.
- Hydrogel Solution 2.5% Alginate w / v (LF200FTS) in 0.5mM SDS
- Extracellular matrix Matrigel® classic (without phenol red and with growth factors)
- Exudation device - 3 x 12ml hamilton syringes containing respectively 2.5% sterile alginate and the other two 300mM sterile sorbitol syringes
- the alginate capsules are obtained according to the method described in Alessandri et al (PNAS 2013, DOI: 10.1073 / pnas.1309482110 and LOC 2016 DOI: 10.1039 / c61c00133e) and in the application WO2013113855.
- the microfluidic coextrusion device for the production of capsules is placed about 50 cm above a petri dish containing the crosslinking solution.
- the alginate solution, the sorbitol solution and the cell solution are then co-injected into the microfluidic coextrusion device, to form composite droplets which are crosslinked by falling into the calcium bath.
- the coextrusion device is operated for 10 seconds, and produces about 5000 alginate capsules per second, totaling about 50,000 capsules.
- the alginate capsules are then recovered by filtering the calcium bath with a 40 ⁇ mesh cell strainer which retains the capsules. These are rinsed with the base of medium then re-suspended in the final medium.
- a potential of + 2kV was applied via an electrode in the alginate.
- a copper ring with a mass of 3 cm in diameter is positioned approximately 1 cm from the tip of the microfluidic coextrusion device to generate the electric field necessary for the electro-formation of the droplets.
- Microcompartmental cells comprising only SUDHL4 or HLY1 lymphoma cells
- the lymphoma cells Prior to encapsulation, the lymphoma cells are cultured in DMEM supplemented with 10% fetal calf serum (FCS) in a humid atmosphere at 37 ° C in the presence of 5% CO 2.
- FCS fetal calf serum
- the cells are centrifuged and resuspended in sorbitol (300 mM) at a rate of 6 to 100.10 6 10.10 ceUules / mL.
- the number of cells per capsule varies between 30 and 100.
- the capsules are cultured in DMEM medium supplemented with 10% FCS in a CO2 oven at 37 ° C.
- the medium is changed every 2 to 3 days.
- the capsules are divided into 96-well plates, one capsule per well.
- the clusters of cells are then periodically imaged (every other day) in phase contrast and in fluorescence if the cell line expresses a fluorescent protein.
- the area of cell clusters is measured using ImageJ® software and growth curves are established ( Figure 1B).
- lymphocytic cells In order to get closer to the microenvironment of a lymph node, lymphocytic cells (DOHH2) are co-cultured with Matrigel® extracellular matrix and "RESTO" type stromal cells.
- DOHH2 lymphocytic cells
- the RESTO cells were previously cultured in DMEM medium supplemented with 10% fetal calf serum in a humid atmosphere at 37 ° C with 5% CCh. At the time of encapsulation, the cells are detached from the support by action of trypsin, and then they are resuspended in the extracellular matrix in the presence of lymphoma cells at a ratio of 1/1.
- the cell density of RESTO cells and lymphoma cells may vary from 10-50.10 6 cells / ml.
- the coextrusion encapsulation method makes it possible to obtain a coating of the inner wall of the alginate capsules by the extracellular matrix.
- This coating allows the adhesion of stromal cells and promotes the formation of the tumor niche. In a few days, the cells organize themselves freely and form a cluster of cohesive cells after 4-10 days of culture (FIG. 3).
- Micro-compartments were made according to the invention from lymphocyte cells from patients with Sezary syndrome (cutaneous T-cell leukemic form). After encapsulation, the cells grow inside the alginate capsules and form a cluster of cells after about ten days ( Figure 12). This confirms that the method according to the invention makes it possible to obtain cellular microcompartments from primary cells of patients, which makes it possible to envisage the use of this method in personalized medicine.
- Example 2 Analysis of cellular microcompartments
- Capsules containing clusters of SUDHL4 or HLY1 cells are placed in agarose wells coated with DMEM medium without phenol red (on D1-D6). The images are acquired using a ZEISS lsm 510 confocal microscope. Two types of analysis are performed: a one-time analysis after marking the microcompartment with a fluorophore, and an analysis using intermittent imaging, after labeling or non-labeling of cells with a fluorophore. The cells are labeled with calcein-AM and propidium iodide to visualize the dead cells; the cell nuclei are marked in blue with Hoechst 33342.
- the paraffin-embedded immunofluorescence technique was adapted to the analysis of the capsules: capsules containing the cell clusters are removed and included in a gelled solution of agarose with a low melting point of 2%. Once gelled, the agarose block containing the capsules is immersed in a 4% paraformaldehyde fixative for 30 minutes. After fixation, the samples are treated according to the protocols conventionally described for immunohistochemistry.
- Ki67 protein which is a marker of cell activation
- cleaved caspase 3 which makes it possible to evaluate cell death
- the extracellular matrix consists mainly of fibronectin, collagen I and laminin. Immunofluorescence analysis showed the presence of these three types of matrix in the cell clusters of microcompartments, whereas the same cells grown in suspension do not express these matrices. D] Dissolution of alginate capsules
- FIG. 4 shows an example of dissolution of a capsule containing a cluster of cells comprising only SUDHL4 lymphoma cells (FIG. 4A) and a capsule containing a cluster of cells comprising DOHH2 lymphoma cells and stromal cells (FIG. 4B). .
- the alginate capsules are dissolved and the clumps of cells dissociated before being incubated with a marker of the apoptosis (TMRM) and then analyzed by flow cytometer in the presence of counting beads (Figure S). Over time, it is observed that the number of cells increases, while the proportions of dead cells within the cell clusters decrease between J3 and J10, which is correlated with the increase in the volume of the spheroid described in Figure 1A .
- TMRM marker of the apoptosis
- FIG. 6 the reconstitution of a tumor niche similar to that found in the lymph node (C: RESTO + DOHH2 cells) promotes the growth of tumor B cells.
- C RESTO + DOHH2 cells
- stromal cells differentiate into pro-tumoral lymphoid stroma (Thomazy et al, 2003, Ohe et al., 2016) expressing, inter alia, transglutaminase 2 (TG2) which has a role in the stabilization of extracellular matrix and cell adhesion.
- TG2 transglutaminase 2
- the Resto-type stromal cell (FRC) culture in the presence of tumor B cells and extracellular matrix leads to the expression of TG2 revealed by immunolabeling.
- FRC Resto-type stromal cell
- TMRM the alginate capsules are previously dissolved and the clumps of dissociated cells
- Preclinical cancer drug research has the worst success rate of any therapeutic trial, with less than 5% of candidate compounds passing phase m clinical trials.
- One of the explanations for these failures is the lack of a relevant model capable of reproducing the spread of drugs within a tumor. Indeed, one of the hypotheses to explain the decrease in the effectiveness of molecules during the transition from pre-clinical tests to clinical trials is that cell density within tumors would slow the penetration and spread of drugs, decreasing their effectiveness.
- the 3D model according to the invention is relevant for studying the diffusion of drugs within a lymphomatous tumor niche.
- doxorubicin which is otherwise used in the standard treatment of B-cell lymphoma
- ECM extracellular matrix
- stromal cells of RESTO type were incubated 24h in the presence or absence of Doxorubicin ( ⁇ ).
- the fluorescence intensity of the cells was then measured by flow cytometry.
- Standard treatment for B-cell lymphoma is conventional multidrug therapy combined with CD20-directed immunotherapy expressed on the surface of mature B cells.
- CD20-directed immunotherapy expressed on the surface of mature B cells.
- the spheroids were incubated on post-encapsulation day-7 in the presence of anti-CD19 AC directly coupled to phycoerythrin (PE) (very strongly expressed in B cells), or
- the diffusion of drugs is impaired in the 3D structures according to the invention.
- the purpose of the present experiment is to verify if this alteration is correlated with a chemoresistance.
- the efficacy of two conventional chemotherapies doxorubicin and etoposide was tested in parallel on cells cultured in suspension (2D) and on clumps of cells from microcompartmental cells according to the invention, containing lymphomatous cells alone. or in the presence of ECM, with or without RESTO stromal cells, treated with increasing concentrations of these chemotherapy molecules.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Sustainable Development (AREA)
- Clinical Laboratory Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1753067A FR3065010A1 (fr) | 2017-04-07 | 2017-04-07 | Microcompartiment de cellules hematopoietiques malignes et procede de preparation d'un tel microcompartiment |
PCT/FR2018/050855 WO2018185439A1 (fr) | 2017-04-07 | 2018-04-05 | Microcompartiment de cellules hématopoïétiques malignes et procédé de préparation d'un tel microcompartiment |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3607056A1 true EP3607056A1 (de) | 2020-02-12 |
Family
ID=59325423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18718897.4A Withdrawn EP3607056A1 (de) | 2017-04-07 | 2018-04-05 | Mikrokompartment maligner hämatopoietischer zellen und verfahren zur herstellung solch eines mikrokompartments |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200370022A1 (de) |
EP (1) | EP3607056A1 (de) |
JP (1) | JP2020524523A (de) |
FR (1) | FR3065010A1 (de) |
WO (1) | WO2018185439A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3134114A1 (fr) * | 2022-04-05 | 2023-10-06 | Treefrog Therapeutics | Microcompartiments cellulaires comprenant des lymphocytes adaptés pour la culture à grande échelle |
FR3134117A1 (fr) * | 2022-04-05 | 2023-10-06 | Treefrog Therapeutics | Microcompartiments cellulaires comprenant des lymphocytes adaptés pour la culture à grande échelle |
FR3134116A1 (fr) * | 2022-04-05 | 2023-10-06 | Treefrog Therapeutics | Microcompartiments cellulaires comprenant des lymphocytes formant une culture groupée en 3D et ayant une faible teneur en TNF alpha |
WO2023194479A1 (fr) * | 2022-04-05 | 2023-10-12 | Treefrog Therapeutics | Microcompartiments cellulaires comprenant des lymphocytes formant une culture groupee en 3d et ayant une faible teneur en granzyme b |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2986165B1 (fr) | 2012-01-31 | 2015-07-24 | Capsum | Procede de preparation de capsules rigidifiees |
-
2017
- 2017-04-07 FR FR1753067A patent/FR3065010A1/fr not_active Withdrawn
-
2018
- 2018-04-05 EP EP18718897.4A patent/EP3607056A1/de not_active Withdrawn
- 2018-04-05 US US16/603,264 patent/US20200370022A1/en not_active Abandoned
- 2018-04-05 WO PCT/FR2018/050855 patent/WO2018185439A1/fr active Application Filing
- 2018-04-05 JP JP2020504449A patent/JP2020524523A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200370022A1 (en) | 2020-11-26 |
WO2018185439A1 (fr) | 2018-10-11 |
JP2020524523A (ja) | 2020-08-20 |
FR3065010A1 (fr) | 2018-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018185439A1 (fr) | Microcompartiment de cellules hématopoïétiques malignes et procédé de préparation d'un tel microcompartiment | |
Spasojevic et al. | Reduction of the inflammatory responses against alginate-poly-L-lysine microcapsules by anti-biofouling surfaces of PEG-b-PLL diblock copolymers | |
EP3713665B1 (de) | Verfahren zur herstellung von kapseln aus einer äusseren hülle aus vernetztem hydrogel, die einen zentralen kern umgibt | |
EP2882290A1 (de) | System zur lebendhaltung und zum transport von hautbiopsien und anwendungen dieses systems | |
Li et al. | Development of a localized drug delivery system with a step-by-step cell internalization capacity for cancer immunotherapy | |
FR2501715A1 (fr) | Procede de culture de cellules necessitant une fixation pour la fabrication de substances therapeutiques | |
Wang et al. | Nanostructured architectures promote the mesenchymal–epithelial transition for invasive cells | |
FR3063736A1 (fr) | Microfibre cellulaire creuse et procede de fabrication d'une telle microfibre cellulaire creuse | |
Zhou et al. | Expansion of ovarian cancer stem-like cells in poly (ethylene glycol)-cross-linked poly (methyl vinyl ether-alt-maleic acid) and alginate double-network hydrogels | |
Brancato et al. | Tumor-stroma interactions alter the sensitivity of drug in breast cancer | |
Rima et al. | Microfluidic harvesting of breast cancer tumor spheroid-derived extracellular vesicles from immobilized microgels for single-vesicle analysis | |
EP3752594B1 (de) | Biokompatibles dreidimensionales netzwerk und seine verwendung als zellträger | |
St‐Denis‐Bissonnette et al. | A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy | |
EP3256568B1 (de) | Verfahren zum implantieren von zellklumpen in einem hautexplantat | |
JP7306647B2 (ja) | 移植片及びその使用 | |
He et al. | Revisiting the advances and challenges in the clinical applications of extracellular vesicles in cancer | |
US11162068B2 (en) | Biomimetic support for three-dimensional cell culturing, method for manufacturing same, and use thereof | |
EP2524031B1 (de) | Menschlicher stammzelllinien und maus: modell von endothelialen progenitorzellen | |
Ramezani et al. | Current knowledge on therapeutic, diagnostic, and prognostics applications of exosomes in multiple myeloma: opportunities and challenges | |
WO2023194479A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes formant une culture groupee en 3d et ayant une faible teneur en granzyme b | |
Wang | Artificial Receptor Display for Cell Surface Engineering | |
Tian et al. | OPEN ACCESS EDITED BY Jin Yan, Xi'an Jiaotong University, China | |
Garmanchouk et al. | Formation of multicellular aggregates under different conditions of microenvironment | |
Sampat | Evaluation of novel combination drug protocols for neuroblastoma using advanced imaging in a chick embryo model | |
Reed | Assessment of the biocompatibility, stability, and suitability of novel thermoresponsive films for the rapid generation of cellular constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191008 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MOURCIN, FREDERIC Inventor name: LATOUR, SIMON Inventor name: TARTE, KARIN Inventor name: BRESSON-BEPOLDIN, LAURENCE Inventor name: MAHOUCHE, ISABELLE Inventor name: ALESSANDRI, KEVIN Inventor name: NASSOY, PIERRE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210527 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20221101 |